// Welcome Message
Dear colleagues and friends,
We are pleased to invite you to participate at the Full-Day Webinar on “Liquid Biopsy in the Clinical Setting”, on Saturday, January 15, 2022, organized by the Hellenic Society of Liquid Biopsy.
Liquid biopsy based on minimally invasive blood tests is today one of the most exciting fields in cancer since it has a high potential to significantly change clinical decision making by providing an extremely powerful clinical tool for the individual molecular profiling of cancer patients in real time.
Liquid biopsy is mainly based on the analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) circulating miRNAs and tumor-derived extracellular vesicles that are shed from primary tumors and their metastatic sites into peripheral blood. Standardization of tests based on Liquid biopsy is now more than ever highly important and thus worldwide efforts are now focusing on that specific aim.
The major advantage of liquid biopsy analysis is that it is minimally invasive, and can be serially repeated, thus allowing extracting information from the tumor in real time. Moreover, the identification of predictive biomarkers in peripheral blood that can monitor response to therapy in real time, holds a very strong potential for novel approaches in the therapeutic management of cancer patients.
In the clinical setting, liquid biopsies are now used to detect minimal residual disease, select patients for specific targeted therapies, and monitor treatment response. A variety of liquid biopsy tests for prognostic and predictive biomarkers are now available in various types of cancer, and based on their clinical performance some have already been cleared by the FDA.
We invite you to join us in the Full-Day Webinar on “Liquid Biopsy in the Clinical Setting”. World class leaders in the field, that are using liquid biopsy in the clinical setting will present state of the art and cutting-edge findings on the latest results of clinical trials based on liquid biopsy.
Evi Lianidou, PhD
Professor, University of Athens,
President of the Hellenic Society of Liquid Biopsy
https://hsliquidbiopsy.wixsite.com/2021
We are pleased to invite you to participate at the Full-Day Webinar on “Liquid Biopsy in the Clinical Setting”, on Saturday, January 15, 2022, organized by the Hellenic Society of Liquid Biopsy.
Liquid biopsy based on minimally invasive blood tests is today one of the most exciting fields in cancer since it has a high potential to significantly change clinical decision making by providing an extremely powerful clinical tool for the individual molecular profiling of cancer patients in real time.
Liquid biopsy is mainly based on the analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) circulating miRNAs and tumor-derived extracellular vesicles that are shed from primary tumors and their metastatic sites into peripheral blood. Standardization of tests based on Liquid biopsy is now more than ever highly important and thus worldwide efforts are now focusing on that specific aim.
The major advantage of liquid biopsy analysis is that it is minimally invasive, and can be serially repeated, thus allowing extracting information from the tumor in real time. Moreover, the identification of predictive biomarkers in peripheral blood that can monitor response to therapy in real time, holds a very strong potential for novel approaches in the therapeutic management of cancer patients.
In the clinical setting, liquid biopsies are now used to detect minimal residual disease, select patients for specific targeted therapies, and monitor treatment response. A variety of liquid biopsy tests for prognostic and predictive biomarkers are now available in various types of cancer, and based on their clinical performance some have already been cleared by the FDA.
We invite you to join us in the Full-Day Webinar on “Liquid Biopsy in the Clinical Setting”. World class leaders in the field, that are using liquid biopsy in the clinical setting will present state of the art and cutting-edge findings on the latest results of clinical trials based on liquid biopsy.
Evi Lianidou, PhD
Professor, University of Athens,
President of the Hellenic Society of Liquid Biopsy
https://hsliquidbiopsy.wixsite.com/2021
//
